Australian court affirms Mylan patent invalidation

The Federal Court of Australia has upheld a patent victory for Indian generic manufacturer Sun Pharma over Mylan in a dispute over cholesterol drug fenofibrate.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

English appeals court refuses Neurim injunction for insomnia drug

26 June 2020 The English Court of Appeal has rejected Neurim’s attempt to block sales of a generic version of its insomnia drug made by Mylan ahead of a patent infringement trial.

Americas

Mylan scores multiple sclerosis patent win over Biogen

23 June 2020 Mylan has succeeded in having a key Biogen patent covering multiple sclerosis drug Tecfidera invalidated by a US federal court.

Americas

Mylan launches Tecfidera generic amid Biogen battle

20 August 2020 Mylan launched its generic version of Biogen’s $4 billion-a-year multiple sclerosis drug Tecfidera yesterday, August 19.

More on this story

Big Pharma

English appeals court refuses Neurim injunction for insomnia drug

26 June 2020 The English Court of Appeal has rejected Neurim’s attempt to block sales of a generic version of its insomnia drug made by Mylan ahead of a patent infringement trial.

Americas

Mylan scores multiple sclerosis patent win over Biogen

23 June 2020 Mylan has succeeded in having a key Biogen patent covering multiple sclerosis drug Tecfidera invalidated by a US federal court.

Americas

Mylan launches Tecfidera generic amid Biogen battle

20 August 2020 Mylan launched its generic version of Biogen’s $4 billion-a-year multiple sclerosis drug Tecfidera yesterday, August 19.

More on this story

Big Pharma

English appeals court refuses Neurim injunction for insomnia drug

26 June 2020 The English Court of Appeal has rejected Neurim’s attempt to block sales of a generic version of its insomnia drug made by Mylan ahead of a patent infringement trial.

Americas

Mylan scores multiple sclerosis patent win over Biogen

23 June 2020 Mylan has succeeded in having a key Biogen patent covering multiple sclerosis drug Tecfidera invalidated by a US federal court.

Americas

Mylan launches Tecfidera generic amid Biogen battle

20 August 2020 Mylan launched its generic version of Biogen’s $4 billion-a-year multiple sclerosis drug Tecfidera yesterday, August 19.